开云app官网登录入口网页版-官方正版

#激动剂#

173篇内容 | 2803人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2215111, encodeId=f5db2215111cf, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a> <a href='/topic/show?id=747de9336a7' target=_blank style='color:#2F92EE;'>#缺氧诱导因子#</a> <a href='/topic/show?id=41ba316e5be' target=_blank style='color:#2F92EE;'>#分子结构#</a>, objectTitle=靶向缺氧诱导因子治疗的机遇与挑战, objectType=article, longId=834338, objectId=44c783433832, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720689632751_92910.jpg, objectUrl=/article/show_article.do?id=44c783433832, replyNumber=0, likeNumber=58, createdTime=2024-07-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=44c783433832, moduleTitle=靶向缺氧诱导因子治疗的机遇与挑战, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=44c783433832)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1627885, encodeId=56c8162e885bb, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, objectType=article, longId=739436, objectId=f1a5e39436f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1a5e39436f8, replyNumber=0, likeNumber=87, createdTime=2022-09-17, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1a5e39436f8, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f1a5e39436f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JAMA Netw Open：前列腺癌治疗药物促性腺激素释放激素激动剂与患糖尿病男性的心血管疾病风险和高血压有关么？, objectType=article, longId=735807, objectId=2b19e35807ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b19e35807ec, replyNumber=0, likeNumber=82, createdTime=2022-08-15, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b19e35807ec, moduleTitle=JAMA Netw Open：前列腺癌治疗药物促性腺激素释放激素激动剂与患糖尿病男性的心血管疾病风险和高血压有关么？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2b19e35807ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627883, encodeId=ed3f162e88375, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=82, createdTime=2022-04-09, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627882, encodeId=60be162e882de, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Transl Res：CD11b激动剂--狼疮性肾炎治疗新方法, objectType=article, longId=301421, objectId=206a30142193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=206a30142193, replyNumber=0, likeNumber=77, createdTime=2022-03-24, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=206a30142193, moduleTitle=Transl Res：CD11b激动剂--狼疮性肾炎治疗新方法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=206a30142193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627881, encodeId=b560162e8814b, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, objectType=article, longId=301367, objectId=c4b830136e91, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b830136e91, replyNumber=0, likeNumber=86, createdTime=2022-03-23, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b830136e91, moduleTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c4b830136e91)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627880, encodeId=cca7162e880c6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JAMA Netw Open：胰高升糖素样肽-1受体激动剂与二肽基肽酶-4抑制剂的使用与2型糖尿病和晚期慢性肾脏疾病患者死亡率的关系, objectType=article, longId=301330, objectId=e46e30133002, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46e30133002, replyNumber=0, likeNumber=84, createdTime=2022-03-23, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46e30133002, moduleTitle=JAMA Netw Open：胰高升糖素样肽-1受体激动剂与二肽基肽酶-4抑制剂的使用与2型糖尿病和晚期慢性肾脏疾病患者死亡率的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e46e30133002)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627878, encodeId=87f0162e87841, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=APT：胰高糖素样肽-1受体激动剂在非酒精性脂肪性肝炎、肥胖和糖尿病中的作用, objectType=article, longId=301055, objectId=3c31301055f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c31301055f6, replyNumber=0, likeNumber=87, createdTime=2022-03-19, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c31301055f6, moduleTitle=APT：胰高糖素样肽-1受体激动剂在非酒精性脂肪性肝炎、肥胖和糖尿病中的作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3c31301055f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627879, encodeId=d7a5162e8792a, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=APT：胰高糖素样肽-1受体激动剂在非酒精性脂肪性肝炎、肥胖和糖尿病中的作用！, objectType=article, longId=300963, objectId=0b32300963be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b32300963be, replyNumber=0, likeNumber=86, createdTime=2022-03-18, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b32300963be, moduleTitle=APT：胰高糖素样肽-1受体激动剂在非酒精性脂肪性肝炎、肥胖和糖尿病中的作用！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0b32300963be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627877, encodeId=46e2162e877b3, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, objectType=article, longId=300317, objectId=525d30031e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525d30031e63, replyNumber=0, likeNumber=71, createdTime=2022-03-10, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525d30031e63, moduleTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=525d30031e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627876, encodeId=5185162e876a6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况, objectType=article, longId=295500, objectId=4e5b295500be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5b295500be, replyNumber=0, likeNumber=89, createdTime=2022-02-13, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5b295500be, moduleTitle=BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4e5b295500be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627875, encodeId=a821162e8753b, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布, objectType=article, longId=295116, objectId=8f862951163b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f862951163b, replyNumber=0, likeNumber=97, createdTime=2022-02-05, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f862951163b, moduleTitle=Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8f862951163b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627874, encodeId=6dc5162e87403, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Pharmacol Res：GIP和GLP-2共同改善支持GIPR-GLP-2R共激动剂作为未来骨质疏松症治疗的人类骨转换, objectType=article, longId=294731, objectId=07dc294e315d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07dc294e315d, replyNumber=0, likeNumber=82, createdTime=2022-01-27, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07dc294e315d, moduleTitle=Pharmacol Res：GIP和GLP-2共同改善支持GIPR-GLP-2R共激动剂作为未来骨质疏松症治疗的人类骨转换, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=07dc294e315d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽, objectType=article, longId=293924, objectId=e7922939240b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7922939240b, replyNumber=0, likeNumber=77, createdTime=2022-01-14, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7922939240b, moduleTitle=JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e7922939240b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627872, encodeId=8c2c162e8728c, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Lancet Psychiatry：药物成瘾性情大变？阿片受体激动剂治疗期间明显降低自残风险！, objectType=article, longId=293615, objectId=c61c29361537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c61c29361537, replyNumber=0, likeNumber=85, createdTime=2022-01-10, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c61c29361537, moduleTitle=Lancet Psychiatry：药物成瘾性情大变？阿片受体激动剂治疗期间明显降低自残风险！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c61c29361537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627871, encodeId=4dab162e871d3, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较, objectType=article, longId=220590, objectId=46c922059001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46c922059001, replyNumber=0, likeNumber=75, createdTime=2021-11-20, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46c922059001, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=46c922059001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627870, encodeId=42d1162e870b1, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用, objectType=article, longId=220548, objectId=8b2c22054893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b2c22054893, replyNumber=0, likeNumber=72, createdTime=2021-11-19, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b2c22054893, moduleTitle=Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8b2c22054893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627869, encodeId=a146162e869b0, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=J Hepatol：口服FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的疗效, objectType=article, longId=220041, objectId=456022004188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456022004188, replyNumber=0, likeNumber=70, createdTime=2021-11-11, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456022004188, moduleTitle=J Hepatol：口服FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=456022004188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627868, encodeId=5cc4162e868a6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析, objectType=article, longId=220003, objectId=76552200039d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76552200039d, replyNumber=0, likeNumber=64, createdTime=2021-11-10, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76552200039d, moduleTitle=Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=76552200039d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627867, encodeId=b22f162e867c8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Circulation：GnRH拮抗剂和激动剂的相对心血管安全性孰高孰低？, objectType=article, longId=218896, objectId=fc4b218896c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc4b218896c7, replyNumber=0, likeNumber=74, createdTime=2021-10-21, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc4b218896c7, moduleTitle=Circulation：GnRH拮抗剂和激动剂的相对心血管安全性孰高孰低？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fc4b218896c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

激动剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#激动剂# #缺氧诱导因子# #分子结构#

靶向缺氧诱导因子治疗的机遇与挑战

2024-07-15发表于上海

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性

2022-09-17

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JAMA Netw Open：前列腺癌治疗药物促性腺激素释放激素激动剂与患糖尿病男性的心血管疾病风险和高血压有关么？

2022-08-15

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2022-04-09

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Transl Res：CD11b激动剂--狼疮性肾炎治疗新方法

2022-03-24

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响

2022-03-23

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JAMA Netw Open：胰高升糖素样肽-1受体激动剂与二肽基肽酶-4抑制剂的使用与2型糖尿病和晚期慢性肾脏疾病患者死亡率的关系

2022-03-23

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

APT：胰高糖素样肽-1受体激动剂在非酒精性脂肪性肝炎、肥胖和糖尿病中的作用

2022-03-19

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

APT：胰高糖素样肽-1受体激动剂在非酒精性脂肪性肝炎、肥胖和糖尿病中的作用！

2022-03-18

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系

2022-03-10

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况

2022-02-13

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布

2022-02-05

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Pharmacol Res：GIP和GLP-2共同改善支持GIPR-GLP-2R共激动剂作为未来骨质疏松症治疗的人类骨转换

2022-01-27

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽

2022-01-14

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Lancet Psychiatry：药物成瘾性情大变？阿片受体激动剂治疗期间明显降低自残风险！

2022-01-10

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较

2021-11-20

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用

2021-11-19

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

J Hepatol：口服FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的疗效

2021-11-11

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析

2021-11-10

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Circulation：GnRH拮抗剂和激动剂的相对心血管安全性孰高孰低？

2021-10-21

科室
- - 订阅+
  - 更多科室
工具
服务